BiotechTube
Plexium

Plexium

San Diego, United States· Est.
plexium.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60.1M

Overview

Plexium is a private, preclinical-stage biotechnology company pioneering a novel approach within the targeted protein degradation (TPD) field through its DELTA Discovery platform. The company is developing monovalent degraders and molecular glues, which could expand the druggable proteome beyond traditional TPD modalities. Backed by experienced leadership and notable life science investors, Plexium is advancing a pipeline of potential first-in-class therapies, though it faces significant technical and competitive risks inherent to early-stage drug discovery.

Small Molecules

Technology Platform

DELTA Discovery platform featuring proprietary ultra-high throughput (uHTS) cell-based screening for the discovery of Monovalent Direct Degraders and Molecular Glues.

Funding History

1
Total raised:$60.1M
Venture$60.1M

Opportunities

Plexium's focus on monovalent degraders and molecular glues addresses key limitations of first-generation bifunctional degraders, potentially enabling the targeting of a wider 'undruggable' proteome with better drug-like properties.
The growing validated TPD market and high unmet need across oncology, neurology, and immunology present a substantial addressable opportunity for novel modalities.

Risk Factors

The company faces high technical risk in discovering and developing unpredictable molecular glue and monovalent degrader compounds.
It operates in an intensely competitive TPD landscape against well-capitalized public companies and pharma, and as a pre-revenue, private entity, it is dependent on successful milestone achievement to secure future financing.

Competitive Landscape

Plexium competes in the targeted protein degradation field against established public companies like Kymera Therapeutics, Arvinas, and Nurix Therapeutics, as well as large pharmaceutical firms with internal TPD efforts. Its differentiation lies in its focus on monovalent and molecular glue degraders, a niche but highly competitive segment also pursued by others like Monte Rosa Therapeutics and Triana Biomedicines.

More companies in Small Molecule Drugs →More companies in United States →